Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
2006

Using FibroTest to Predict Liver Fibrosis in Non-Alcoholic Fatty Liver Disease

Sample size: 267 publication 10 minutes Evidence: moderate

Author Information

Author(s): Vlad Ratziu, Julien Massard, Frederic Charlotte, Djamila Messous, Françoise Imbert-Bismut, Luninita Bonyhay, Mohamed Tahiri, Mona Munteanu, Dominique Thabut, Jean François Cadranel, Brigitte Le Bail, Victor de Ledinghen, Thierry Poynard

Primary Institution: AP-HP Groupe Hospitalier Pitié-Salpêtrière, Paris, France

Hypothesis

The diagnostic utility of FibroTest for detecting advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) is validated.

Conclusion

FibroTest reliably predicts advanced fibrosis in patients with NAFLD.

Supporting Evidence

  • FibroTest showed a 90% negative predictive value for advanced fibrosis.
  • An FT cutoff of 0.30 had a sensitivity of 77% for detecting advanced fibrosis.
  • An FT cutoff of 0.70 had a specificity of 98% for advanced fibrosis.
  • The study included 170 patients in a single center and 97 in a multicenter study.
  • FibroTest was validated against liver biopsy results.
  • Patients with advanced fibrosis were older and had higher levels of certain biomarkers.
  • Discordance between FibroTest and biopsy results was noted in some cases.
  • FT provides a continuous quantitative assessment of liver fibrosis.

Takeaway

Doctors can use a simple blood test called FibroTest to check if people with fatty liver disease have serious liver damage without needing a painful liver biopsy.

Methodology

170 patients with suspected NAFLD were included in a reference center and 97 in a multicenter study, with 954 blood donors as controls; fibrosis was assessed using a histological scale and FibroTest scores.

Potential Biases

Potential biases include sampling variability in liver biopsy and discordance between biopsy results and FibroTest predictions.

Limitations

The study may have selection bias due to the nature of the patient groups and the reliance on biopsy for validation.

Participant Demographics

Patients included were adults with suspected NAFLD, with a mean age of 52.8 years in Group 1 and 48.5 years in Group 2.

Statistical Information

P-Value

P = 0.10 for advanced fibrosis detection comparison between groups.

Confidence Interval

95% CI 0.77–0.91 for advanced fibrosis detection.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-230X-6-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication